GlassScriptPhysician profile
Craig Wilkenfeld
NPI 1194828905
$3,070.43
in general payments reported to CMS, 2019-2025
31 companies · $368 in 2025
The $368 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $592 · 2020: $210 · 2021: $246 · 2022: $586 · 2023: $548 · 2024: $520 · 2025: $368.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,435.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,435.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $586.86 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $344.79 | 2019-2023 | Xarelto |
| Pfizer INC. | $306.96 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $253.42 | 2019-2025 | Camzyos, Eliquis |
| Cvrx, INC. | $238.71 | 2022-2024 | Barostim Neo System |
| Merck Sharp & Dohme LLC | $225.52 | 2021-2025 | Verquvo, Capvaxive |
| Amgen INC. | $166.18 | 2019-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $112.71 | 2019-2025 | Lifevest |
| Heartflow, INC. | $97.37 | 2024-2025 | |
| Philips North America LLC | $89.83 | 2022-2025 | Mcot, (Ck4) Mcot |
| Baxter Healthcare | $82.03 | 2023-2025 | Hillrom - Cardiac Ambulatory Monitor |
| Novo Nordisk INC | $61.19 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Irhythm Technologies, INC. | $49.99 | 2019-2024 | Zio Monitor, Zio Xt Patch |
| Esperion Therapeutics, INC. | $40.62 | 2022-2025 | Nexletol |
| Abbott Laboratories | $40.39 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $39.05 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.04 | 2019-2023 | Jardiance |
| Boston Scientific Corporation | $35.00 | 2019-2020 | |
| Angiodynamics, INC. | $34.61 | 2019 | |
| Alnylam Pharmaceuticals INC. | $29.30 | 2019-2024 | Amvuttra |
| Chiesi USA, INC. | $29.24 | 2019 | |
| Gilead Sciences, INC. | $28.64 | 2019 | |
| Portola Pharmaceuticals, LLC | $27.62 | 2019-2020 | |
| Impulse Dynamics (USA) INC. | $15.79 | 2024 | Optimizer |
| Bardy Diagnostics, INC. | $15.00 | 2021 | |
| Medtronic Vascular, INC. | $15.00 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $14.72 | 2024 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $14.42 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $13.70 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $11.72 | 2019 | |
| Lundbeck LLC | $11.01 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Craig Wilkenfeld listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.